{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:20:13Z","timestamp":1790306413694,"version":"4.1.0"},"reference-count":153,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.leukres.2005.12.018","type":"journal-article","created":{"date-parts":[[2006,2,20]],"date-time":"2006-02-20T15:24:56Z","timestamp":1140449096000},"page":"1217-1225","source":"Crossref","is-referenced-by-count":42,"title":["Statins in the treatment of polycythaemia vera and allied disorders: An antithrombotic and cytoreductive potential?"],"prefix":"10.1016","volume":"30","author":[{"given":"Hans Carl","family":"Hasselbalch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline H.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.leukres.2005.12.018_bib1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0268-960X(97)90022-9","article-title":"Idiopathic myelofibrosis: pathogenesis, natural history and management","volume":"11","author":"Reilly","year":"1997","journal-title":"Blood Rev"},{"issue":"Suppl. 2","key":"10.1016\/j.leukres.2005.12.018_bib2","first-page":"3","article-title":"The chronic myeloproliferative disorders","volume":"36","author":"Tefferi","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2005.12.018_bib3","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N Engl J Med"},{"issue":"2 Suppl. 3","key":"10.1016\/j.leukres.2005.12.018_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.seminhematol.2004.02.011","article-title":"The chronic myeloproliferative disorders: clonality and clinical heterogeneity","volume":"41","author":"Spivak","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2005.12.018_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia","volume":"128","author":"Elliot","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2005.12.018_bib6","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","article-title":"Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomised clinical trial","volume":"110","author":"Finazzi","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2005.12.018_bib7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajh.10375","article-title":"Acute leukemia and myelodysplasia in patients with philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan","volume":"74","author":"Nielsen","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2005.12.018_bib8","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera. An analysis of 1,638 patients enroled in a prospective observational study","volume":"105","author":"Finnazi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.12.018_bib9","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8","article-title":"Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy","volume":"83","author":"Gilbert","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2005.12.018_bib10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s002770050554","article-title":"The role of interferon-alpha in the treatment of idiopathic myelofibrosis","volume":"78","author":"Bachleitner-Hofmann","year":"1999","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2005.12.018_bib11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/cncr.11486","article-title":"Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders","volume":"98","author":"Radin","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2005.12.018_bib12","first-page":"520","article-title":"Adverse effects and benefits of two years treatment for thrombocythemia in chronic myeloproliferative disorders","volume":"89","author":"Birgegard","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2005.12.018_bib13","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/cncr.20646","article-title":"Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile","volume":"101","author":"Steurer","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2005.12.018_bib14","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1080\/1042819021000040008","article-title":"Thalidomide in myelofibrosis with myeloid metaplasia: a pooled analysis of individual patient data from five studies","volume":"43","author":"Barosi","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2005.12.018_bib15","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1182\/blood-2001-12-0154","article-title":"Phase 2 trial of imatiib mesylate in myelofibrosis with myeloid metaplasia","volume":"99","author":"Tefferi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.12.018_bib16","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ajh.10431","article-title":"Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis","volume":"74","author":"Hasselbalch","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2005.12.018_bib17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00000441-200303000-00007","article-title":"Polycythemia vera responds to imatinib mesylate","volume":"325","author":"Jones","year":"2003","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.leukres.2005.12.018_bib18","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/sj.leu.2402938","article-title":"Imatinib mesylate (Gleevec\u2122) reduces phlebotomy requirements in polycythemia vera","volume":"17","author":"Silver","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2005.12.018_bib19","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.4747.4747","article-title":"Imatinib mesylate in polycythemia vera. A heterogeneous response pattern but a consistent reduction in phlebotomy requirements","volume":"104","author":"Hasselbalch","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.12.018_bib20","article-title":"A phase 2 consortium (P2C) trial of R115777 (Zarnestra) in myelofibrosis with myeloid metaplasia","volume":"102","author":"Mesa","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.12.018_bib21","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2002-07-1973","article-title":"Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.12.018_bib22","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1080\/10428190412331272677","article-title":"Clinical activity of farnesyltransferase inhibitors in hematologic malignancies: possible mechanisms of action","volume":"45","author":"Jabbour","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2005.12.018_bib23","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1182\/blood-2004-07-2949","article-title":"Farnesyltransferase inhibitor tipifarnib (Zarnestra R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells","volume":"105","author":"Larghero","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.12.018_bib24","first-page":"2023","article-title":"Selective inhibition of primary acute myeloid leukaemia cell growth by simvastatin","volume":"8","author":"Newman","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2005.12.018_bib25","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3109\/10428199709055590","article-title":"A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin, and pravastatin on leukaemic and normal bone marrow progenitors","volume":"24","author":"Newman","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2005.12.018_bib26","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood.V93.4.1308","article-title":"Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach","volume":"93","author":"Dimitroulakos","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.12.018_bib27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/10428190009054894","article-title":"Lovastatin induces a pronounced differentiation response in acute myeloid leukaemias","volume":"40","author":"Dimitroulakos","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2005.12.018_bib28","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/sj.leu.2402196","article-title":"Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells","volume":"15","author":"Xia","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2005.12.018_bib29","first-page":"2067","article-title":"Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin","volume":"7","author":"Wong","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2005.12.018_bib30","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0301-472X(03)00192-9","article-title":"Simvastatin induces apoptosis of B-CLL cells by activation of mitochrondial caspase 9","volume":"31","author":"Chapman-Shimshoni","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2005.12.018_bib31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10623320303358","article-title":"Potential anticancer effects of statins: facts or fiction?","volume":"10","author":"Kaushal","year":"2003","journal-title":"Endothelium"},{"key":"10.1016\/j.leukres.2005.12.018_bib32","first-page":"10","article-title":"The statins as anticancer agents","volume":"9","author":"Chan","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2005.12.018_bib33","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood-2002-07-2283","article-title":"Cholesterol-modulating agents kill acute myeloid leukaemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses","volume":"101","author":"Li","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.12.018_bib34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0145-2126(02)00085-1","article-title":"Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression","volume":"27","author":"Stirewalt","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2005.12.018_bib35","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1182\/blood-2004-06-2462","article-title":"Reducing cholesterol and overcoming drug resistance","volume":"104","author":"Grant","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.12.018_bib36","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood-2004-01-0395","article-title":"Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukaemia cells","volume":"104","author":"Banker","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.12.018_bib37","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood-2003-12-4218","article-title":"The HMG-CoA reductase inhibitor simvastatin overcomes cell-adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase","volume":"104","author":"Schmidmaier","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.12.018_bib38","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ctrv.2004.06.010","article-title":"Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer","volume":"30","author":"Graff","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.leukres.2005.12.018_bib39","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1056\/NEJMoa043792","article-title":"Stains and the risk of cancer","volume":"352","author":"Poynter","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2005.12.018_bib40","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.leukres.2004.10.007","article-title":"Lovastatin alters isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo","volume":"29","author":"Lewis","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2005.12.018_bib41","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/carcin\/bgi036","article-title":"Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells","volume":"26","author":"Cafforio","year":"2005","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.leukres.2005.12.018_bib42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/1043-6618(95)80042-5","article-title":"Pharmacology of competetive inhibitors of HMG-CoA reductase","volume":"31","author":"Corsini","year":"1995","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.leukres.2005.12.018_bib43","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update","volume":"1","author":"Schacter","year":"2005","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.leukres.2005.12.018_bib44","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1001\/jama.279.20.1643","article-title":"Anti-atherothrombotic properties of statins-implications for cardiovascular event reduction","volume":"279","author":"Rosenson","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.leukres.2005.12.018_bib45","first-page":"166","article-title":"Statins as cellular antithrombotics","volume":"29","author":"Fenton","year":"1999","journal-title":"Haemostasis"},{"key":"10.1016\/j.leukres.2005.12.018_bib46","first-page":"1305","article-title":"The anti-thrombotic effects of statins","volume":"33","author":"Kearney","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.leukres.2005.12.018_bib47","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1161\/01.STR.31.10.2442","article-title":"Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice","volume":"31","author":"Laufs","year":"2000","journal-title":"Stroke"},{"key":"10.1016\/j.leukres.2005.12.018_bib48","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0008-6363(00)00247-9","article-title":"Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease","volume":"49","author":"Lefer","year":"2001","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.leukres.2005.12.018_bib49","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9149(01)01643-5","article-title":"Pleiotropic effects of statins and their clinical significance","volume":"88","author":"LaRosa","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.leukres.2005.12.018_bib50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0167-5273(02)00195-X","article-title":"Beyond lipid lowering: the role of statins in vascular protection","volume":"86","author":"Liao","year":"2002","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.leukres.2005.12.018_bib51","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0195-668X(02)00419-0","article-title":"Statin effects beyond lipid lowering\u2014are they clinically relevant?","volume":"24","author":"Bonetti","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.leukres.2005.12.018_bib52","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2143\/AC.59.3.2005187","article-title":"The effect of atorvastatin on platelet function in patients with coronary artery disease","volume":"59","author":"Tekten","year":"2004","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.leukres.2005.12.018_bib53","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.amjcard.2004.04.037","article-title":"Effect of atorvastatin on the expression of CD40 ligand and P-selectin on platelets in patients with hypercholesterolemia","volume":"94","author":"Hwang","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.leukres.2005.12.018_bib54","doi-asserted-by":"crossref","first-page":"31725","DOI":"10.1074\/jbc.272.50.31725","article-title":"Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase","volume":"272","author":"Laufs","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2005.12.018_bib55","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/hc0602.103393","article-title":"Statins have biphasic effects on angiogenesis","volume":"105","author":"Weis","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.leukres.2005.12.018_bib56","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1055\/s-0037-1616260","article-title":"Diverse effects of statins on endothelial cells?","volume":"93","author":"Ferrara","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.leukres.2005.12.018_bib57","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/(SICI)1096-8652(199802)57:2<109::AID-AJH3>3.0.CO;2-#","article-title":"Increased levels of the soluble adhesion molecule E-selectin in patients with chronic myeloproliferative disorders and thromboembolic complications","volume":"57","author":"Musolino","year":"1998","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2005.12.018_bib58","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1046\/j.1365-2141.2001.03092.x","article-title":"Endothelial dysfunction in patients with polycythaemia vera","volume":"115","author":"Neunteufl","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2005.12.018_bib59","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ajh.10054","article-title":"Frequent occurrence of anticardiolipin antibodies, factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders","volume":"69","author":"Jensen","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2005.12.018_bib60","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/343425a0","article-title":"Regulation of the mevalonate pathway","volume":"343","author":"Goldstein","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2005.12.018_bib61","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1126\/science.275.5307.1750","article-title":"Protein prenylation, et cetera: signal transduction in two dimensions","volume":"275","author":"Gelb","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.leukres.2005.12.018_bib62","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1182\/blood.V94.9.2971","article-title":"Ras proteins: recent advances and new functions","volume":"94","author":"Rebello","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.12.018_bib63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0092-8674(00)80601-7","article-title":"New insights into the interaction of Ras with the cell membrane","volume":"98","author":"Magee","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2005.12.018_bib64","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood.V96.5.1655","article-title":"Targeting the Ras signalling pathway: a rational, mechanism-based treatment of hematologic malignancies?","volume":"96","author":"Reuter","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.12.018_bib65","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1042\/0264-6021:3480241","article-title":"Rho GTPases and their effector proteins","volume":"348","author":"Bishop","year":"2000","journal-title":"Biochem J"},{"key":"10.1016\/j.leukres.2005.12.018_bib66","first-page":"3133","article-title":"Lovastatin-induced inhibition of HL-60cell proliferation via cell cycle arrest and apoptosis","volume":"19","author":"Park","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.leukres.2005.12.018_bib67","first-page":"2223","article-title":"Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells","volume":"5","author":"Agarwal","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2005.12.018_bib68","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0021-9150(01)00613-X","article-title":"3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation","volume":"161","author":"Blanco-Colio","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.leukres.2005.12.018_bib69","doi-asserted-by":"crossref","first-page":"38353","DOI":"10.1074\/jbc.M404838200","article-title":"Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonate depletion","volume":"279","author":"Siddals","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2005.12.018_bib70","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/79510","article-title":"The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals","volume":"6","author":"Kureishi","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.leukres.2005.12.018_bib71","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/01.RES.0000014081.30867.F8","article-title":"Double-edged role of statins in angiogenesis signaling","volume":"90","author":"Urbich","year":"2002","journal-title":"Circ Res"},{"key":"10.1016\/j.leukres.2005.12.018_bib72","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1161\/01.ATV.0000012283.15789.67","article-title":"Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibits endothelial proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models","volume":"22","author":"Vincent","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.leukres.2005.12.018_bib73","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1055\/s-0037-1613384","article-title":"Insights in the molecular mechanisms of the anti-angiogenic effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase","volume":"89","author":"Vincent","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.leukres.2005.12.018_bib74","first-page":"1023","article-title":"Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro","volume":"145","author":"Nicosia","year":"1994","journal-title":"Am J Pathol"},{"key":"10.1016\/j.leukres.2005.12.018_bib75","doi-asserted-by":"crossref","first-page":"29483","DOI":"10.1074\/jbc.271.46.29483","article-title":"Induction of vascular endothelial growth factor by insulin-like growth factor I in colorectal carcinoma","volume":"271","author":"Warren","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2005.12.018_bib76","first-page":"4008","article-title":"Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I","volume":"58","author":"Akagi","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2005.12.018_bib77","doi-asserted-by":"crossref","first-page":"24F","DOI":"10.1016\/j.amjcard.2005.06.009","article-title":"Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol","volume":"96","author":"Liao","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.leukres.2005.12.018_bib78","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1161\/01.ATV.15.2.247","article-title":"Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia","volume":"15","author":"Notarbartolo","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.leukres.2005.12.018_bib79","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00004872-199401000-00009","article-title":"Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems","volume":"12","author":"Lijnen","year":"1994","journal-title":"J Hypertens"},{"key":"10.1016\/j.leukres.2005.12.018_bib80","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00001721-200408000-00004","article-title":"Increased soluble CD40L levels are reduced by long term simvastatin in peritoneally dialyzed patients","volume":"15","author":"Malyszko","year":"2004","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.leukres.2005.12.018_bib81","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1083\/jcb.200105058","article-title":"Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis","volume":"154","author":"Lindemann","year":"2001","journal-title":"J Cell Biol"},{"key":"10.1016\/j.leukres.2005.12.018_bib82","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/01.CIR.0000025419.95769.F0","article-title":"Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy","volume":"106","author":"Cippolone","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.leukres.2005.12.018_bib83","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0008-6363(03)00515-7","article-title":"Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells","volume":"59","author":"Mulhaupt","year":"2003","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.leukres.2005.12.018_bib84","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.amjcard.2004.04.037","article-title":"Effect of atorvastatin on the expression of CD40 ligand and P-selectin on platelets in patients with hypercholesterolemia","volume":"94","author":"Hwang","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.leukres.2005.12.018_bib85","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/01.mbc.0000161563.36270.a2","article-title":"CD40-ligand-dependent induction of COX-2 expression in endothelial cells by activated platelets: inhibitory effects of atorvastatin","volume":"16","author":"Mosheimer","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.leukres.2005.12.018_bib86","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0192-0561(96)00068-9","article-title":"Inhibitory effect of fluvastatin, a HMG-CoA reductase inhibitor on the expression of adhesion molecules on human monocyte cell line","volume":"18","author":"Niwa","year":"1996","journal-title":"Int J Immunopharmacol"},{"key":"10.1016\/j.leukres.2005.12.018_bib87","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/01.ATV.19.12.2894","article-title":"Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats","volume":"19","author":"Pruefer","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.leukres.2005.12.018_bib88","first-page":"183","article-title":"Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholestreolemic patients: role of nitric oxide","volume":"48","author":"Romano","year":"2000","journal-title":"J Invest Med"},{"key":"10.1016\/j.leukres.2005.12.018_bib89","doi-asserted-by":"crossref","first-page":"46849","DOI":"10.1074\/jbc.M104197200","article-title":"Modulation of COX-2 expression by statins in human aortic smooth muscle cells: involvement of geranylgeranylated proteins","volume":"276","author":"Degraeve","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2005.12.018_bib90","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/10623320303359","article-title":"Modulation of coagulation and fibrinolytic pathways by statins","volume":"10","author":"Eto","year":"2003","journal-title":"Endothelium"},{"key":"10.1016\/j.leukres.2005.12.018_bib91","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0021-9150(00)00454-8","article-title":"Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells","volume":"152","author":"Lopez","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.leukres.2005.12.018_bib92","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/01.ATV.0000012802.69414.A8","article-title":"Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering","volume":"22","author":"Baetta","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.leukres.2005.12.018_bib93","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/00001721-200309000-00010","article-title":"Statins increase thrombomodulin expression and function in human endothelial cells by a mitric oxide-dependent mechanism and counteract tumor necrosis factor-alpha-induced thrombomodulin downregulation","volume":"14","author":"Shi","year":"2003","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.leukres.2005.12.018_bib94","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1161\/01.CIR.100.2.178","article-title":"Simvastatin preserves the ishemic-reperfused myocardium in normocholesterolemic rat hearts","volume":"100","author":"Lefer","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.leukres.2005.12.018_bib95","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.100.3.230","article-title":"Long-term effects of pravastatin on plasma concentrations of C-reactive protein","volume":"100","author":"Ridker","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.leukres.2005.12.018_bib96","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1161\/01.CIR.103.9.1191","article-title":"Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia","volume":"103","author":"Ridker","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.leukres.2005.12.018_bib97","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1161\/01.CIR.97.20.2007","article-title":"C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction","volume":"97","author":"Ridker","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.leukres.2005.12.018_bib98","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/01.CIR.99.2.237","volume":"99","author":"Koenig","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.leukres.2005.12.018_bib99","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0002-9149(99)00491-9","article-title":"Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men","volume":"84","author":"Rohde","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.leukres.2005.12.018_bib100","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2005.12.018_bib101","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(98)05917-0","article-title":"Inhibition of proinflammatory cytokine production by pravastatin","volume":"353","author":"Rosenson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2005.12.018_bib102","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1042\/CS20030148","article-title":"Statins and their role in vascular protection","volume":"105","author":"Mason","year":"2003","journal-title":"Clin Sci"},{"key":"10.1016\/j.leukres.2005.12.018_bib103","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2141.1985.tb07465.x","article-title":"Endothelial cell proliferation in myelofibrosis","volume":"60","author":"Reilly","year":"1985","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2005.12.018_bib104","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2141.1992.tb08905.x","article-title":"Vascular architecture and collagen type IV in primarymyelofibrosis and polycythaemia vera: an immunomorphomeric study on trephine biopsies of bone marrow","volume":"80","author":"Thiele","year":"1992","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2005.12.018_bib105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0002-9440(10)64511-7","article-title":"Bone marrow in polycythemia vera, chronic myelocytic leukemia and myelofibrosis has an increased vascularity","volume":"157","author":"Lundberg","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.leukres.2005.12.018_bib106","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1600-0609.2004.00235.x","article-title":"Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression","volume":"72","author":"Panteli","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2005.12.018_bib107","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1365-2141.2004.04829.x","article-title":"Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia","volume":"124","author":"Barosi","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2005.12.018_bib108","first-page":"1454","article-title":"Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia","volume":"89","author":"Arora","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2005.12.018_bib109","unstructured":"Castro-Malaspina H. Pathogenesis of myelofibrosis: role of ineffective megakaryopoiesis and megakaryocyte components. In: Myelofibrosis and the biology of connective tissue. New York: Alan R. Liss, Inc.; 1984. p. 427\u2013454."},{"key":"10.1016\/j.leukres.2005.12.018_bib110","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s002770050595","article-title":"Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis","volume":"78","author":"Le Bousse-Kerdiles","year":"1999","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2005.12.018_bib111","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/sj.leu.2402124","article-title":"Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis","volume":"15","author":"Raimundo","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2005.12.018_bib112","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0145-2126(02)00053-X","article-title":"Increased serum levels of vascular endothelial growth factor correlate with splenomegaly in polycythemia vera","volume":"26","author":"Murphy","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2005.12.018_bib113","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ajh.10020","article-title":"Soluble angiogenic factors: implications for chronic myeloproliferative disorders","volume":"69","author":"Musolino","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2005.12.018_bib114","first-page":"S72","article-title":"Angiogenesis in hematological malignancies","volume":"81","author":"Mesters","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2005.12.018_bib115","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/blood-2004-07-2909","article-title":"The pathophysiological role of VEGF in hematological malignancies: therapeutic implications","volume":"105","author":"Podar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.12.018_bib116","first-page":"22227","article-title":"Lovastatin inhibits platelet-derived growth factor (PDGF) stimulation of phosphatidylinositol 3-kinase activity as well as association of p85 subunit to tyrosine-phosphorylated PDGF receptor","volume":"268","author":"McGuire","year":"1993","journal-title":"J Biol Biochem"},{"key":"10.1016\/j.leukres.2005.12.018_bib117","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1006\/bbrc.1994.2472","article-title":"Lovastatin disrupts early events in insulin signaling: a potential mechanism of lovastatin's anti-mitogenic activity","volume":"204","author":"McGuire","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2005.12.018_bib118","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1440-1681.1995.tb02935.x","article-title":"Effect of lovastatin and fluoromevalonate on phosphatidylinositol 3-kinase activity stimulated with PDGF","volume":"22","author":"Iwama","year":"1995","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.leukres.2005.12.018_bib119","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1006\/abbi.1996.0070","article-title":"Lovastatin inhibits the stimulation of mitogen-activated protein kinase by insulin in HIRcB fibroblasts","volume":"326","author":"Xu","year":"1996","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.leukres.2005.12.018_bib120","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1078\/0171-9335-00155","article-title":"Lovastatin blocks basic fibroblast growth factor-induced mitogen-activated protein kinase signaling in coronary smooth muscle cells via phosphatase inhibition","volume":"80","author":"Skaletz-Rorowski","year":"2001","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.leukres.2005.12.018_bib121","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1160\/TH04-09-0592","article-title":"The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis","volume":"93","author":"Alfano","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.leukres.2005.12.018_bib122","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/10428190290011958","article-title":"The insulin-like growth factor system in haematopoietic cells","volume":"43","author":"Zumkeller","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2005.12.018_bib123","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0304-3835(03)00159-9","article-title":"The insulin-like growth factor system and cancer","volume":"195","author":"LeRoith","year":"2003","journal-title":"Cancer Lett"},{"key":"10.1016\/j.leukres.2005.12.018_bib124","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrc1387","article-title":"Insulin-like growth factors and neoplasia","volume":"4","author":"Pollak","year":"2004","journal-title":"Nat Rev"},{"key":"10.1016\/j.leukres.2005.12.018_bib125","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1535-6108(04)00050-9","article-title":"Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematological malignancies, and solid tumors","volume":"5","author":"Mitsiades","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2005.12.018_bib126","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1182\/blood.V78.11.2823.2823","article-title":"Production of erythropoietic bursts by progenitor cells from adult human peripheral blood in an improved serum-free medium: role of insulin like growth factor I","volume":"78","author":"Correa","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.12.018_bib127","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1182\/blood-2003-08-2955","article-title":"Insulin-like growth factor 2 expressed in a novel fetal liver cell population is a growth factor for hematopoietic stem cells","volume":"103","author":"Zhang","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.12.018_bib128","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1182\/blood.V83.1.99.99","article-title":"Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium","volume":"83","author":"Correra","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.12.018_bib129","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood.V89.6.1862","article-title":"Insulin-like growth factor binding protein is elevated in patients with polycythemia vera and stimulates erythroid burst formation in vitro","volume":"89","author":"Mirza","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.12.018_bib130","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.leukres.2004.03.009","article-title":"Aberrant expression of insulin-like growth factor-2 (IGF-2) in Philadelphia chromosome negative chronic myeloproliferative disorders","volume":"28","author":"Bock","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2005.12.018_bib131","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2005.12.018_bib132","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2005.12.018_bib133","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2005.12.018_bib134","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocytosis, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2005.12.018_bib135","doi-asserted-by":"crossref","unstructured":"Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162\u20132168.","DOI":"10.1182\/blood-2005-03-1320"},{"key":"10.1016\/j.leukres.2005.12.018_bib136","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","article-title":"Jak2 is essential for signaling through a variety of cytokine receptors","volume":"93","author":"Parganas","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2005.12.018_bib137","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1097\/01.LAB.0000032411.41603.C2","article-title":"Impact of insulin-like growth factor receptor-1 function on angiogenesis, growth and metastasis of colon cancer","volume":"82","author":"Reinmuth","year":"2002","journal-title":"Lab Invest"},{"key":"10.1016\/j.leukres.2005.12.018_bib138","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/j.seminhematol.2004.02.007","article-title":"Treatment paradigms in the management of chronic myeloproliferative disorders","volume":"41","author":"Fruchtman","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2005.12.018_bib139","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2362.2005.01446.x","article-title":"Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients","volume":"35","author":"Pucetti","year":"2005","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.leukres.2005.12.018_bib140","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.CIR.97.12.1129","article-title":"Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors","volume":"97","author":"Laufs","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.leukres.2005.12.018_bib141","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low dose aspirin in polycythemia vera","volume":"350","author":"Landolphi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2005.12.018_bib142","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.exphem.2005.01.015","article-title":"Leucocyte\u2013platelet interaction in patients with essential thrombocythemia and polycythemia vera","volume":"33","author":"Falanga","year":"2005","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2005.12.018_bib143","first-page":"41","article-title":"Recent advances in platelet\u2013polymorphonuclear leucocyte interaction","volume":"29","author":"de Gaetoano","year":"1999","journal-title":"Haemostasis"},{"key":"10.1016\/j.leukres.2005.12.018_bib144","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1034\/j.1600-0609.2001.00359.x","article-title":"Increased circulating platelet\u2013leucocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count","volume":"66","author":"Jensen","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2005.12.018_bib145","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/01.ATV.0000018306.68268.86","article-title":"Rho-GTPase-dependent platelet\u2013neutrophil interaction affected by HMG-CoA reductase inhibition with altered adenosine nucleotide release and function","volume":"22","author":"Kaneider","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.leukres.2005.12.018_bib146","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood.V80.8.1965.1965","article-title":"Increased thromboxane biosynthesis in patients with polycythaemia vera: evidence for aspirin suppressible platelet activation in vivo","volume":"80","author":"Landolphi","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.12.018_bib147","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1055\/s-0038-1649916","article-title":"Increased thromboxane biosynthesis in essential thrombocythemia","volume":"74","author":"Rocca","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.leukres.2005.12.018_bib148","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S0735-1097(99)00023-6","article-title":"Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia","volume":"33","author":"Szczelik","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.leukres.2005.12.018_bib149","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1056\/NEJM200106283442609","article-title":"Statins and the acute-phase response","volume":"344","author":"Munford","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2005.12.018_bib150","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2005.12.018_bib151","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa042000","article-title":"Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease","volume":"352","author":"Nissen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2005.12.018_bib152","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2005.12.018_bib153","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0306-9877(03)00124-5","article-title":"Statins may potentiate biphosphonates anticancer properties: a new pharmacological approach?","volume":"61","author":"Vincenzi","year":"2003","journal-title":"Med Hypotheses"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212606000191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212606000191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T04:22:52Z","timestamp":1627100572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212606000191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":153,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0145212606000191"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2005.12.018","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}